An interim analysis published by NEJM added new data to the previous meta-analysis and found that Avandia (Rosigilitazone) is associated with an increased risk of myocardial infarction.
BMJ published an editorial, "Rosiglitazone and implications for pharmacovigilance: postsurveillance data should be systematically collected and publicly available." Kazi D. BMJ 2007; 334: 1233-4 (16 June) and concluded that "the ongoing use of rosiglitazone merits careful deliberation." ( You can access the full text with an Athens password).
The author said that pharmacovigilance is the weakest in the regulatory processes of drug safety on both sides of the Atlantic and called for a radical change in the culture of existing regulatory agencies.
No comments:
Post a Comment